Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise.[7][8] It contains insulin degludec and liraglutide.[7][8] It is administered by subcutaneous injection.[7][8]
| Combination of | |
|---|---|
| Insulin degludec | Insulin analog |
| Liraglutide | Glucagon-like peptide-1 receptor agonist (GLP-1) |
| Clinical data | |
| Trade names | Xultophy |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The most common side effects include hypoglycaemia (low blood glucose).[8] Side effects on the digestive system include nausea (feeling sick), diarrhea, vomiting, constipation, dyspepsia (indigestion), gastritis (inflammation of the stomach), abdominal pain (stomach ache), flatulence (wind), gastroesophageal reflux disease (passage of stomach acid back up towards the mouth), and distension (swelling) of the belly.[8]
Insulin degludec is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.[8] By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.[8] Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time.[8]
Liraglutide belongs to the class of diabetes medicines known as GLP-1 receptor agonists[8] It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food.[8] This helps with the control of blood glucose levels.[8]
History
editInsulin degludec/liraglutide was approved for medical use in the European Union in September 2014,[8] and in the United States in November 2016.[9][10]
References
edit- ^ "Australian Public Assessment Report for insulin degludec/liraglutide" (PDF). Therapeutic Goods Administration (TGA). Australian Government. March 2021.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Summary for ARTG Entry: 328580 XULTOPHY insulin degludec 100 units/mL liraglutide 3.6 mg/mL solution for injection pre-filled pen 3 mL". Therapeutic Goods Administration (TGA). Australian Government.
- ^ "Regulatory Decision Summary - Xultophy". Health Canada. 23 October 2014. Retrieved 7 June 2022.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ "Xultophy 100 units/ml insulin degludec + 3.6 mg/mL liraglutide solution for injection in a pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 8 October 2019. Retrieved 15 May 2020.
- ^ a b c d "Xultophy 100/3.6 (- insulin degludec and liraglutide injection, solution". DailyMed. 15 November 2019. Retrieved 15 May 2020.
- ^ a b c d e f g h i j k l m "Xultophy EPAR". European Medicines Agency (EMA). 21 November 2014. Retrieved 15 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Xultophy 100/3.6 (insulin degludec and liraglutide) Injection". U.S. Food and Drug Administration (FDA). 27 November 2017. Retrieved 15 May 2020.
- ^ "Xultophy: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). 23 March 2020. Retrieved 15 May 2020.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |